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Background
With next gen sequencing, the human genome can be
sequenced in a few weeks and for a few thousand dol-
lars. Capability is no longer the issue: interpretation is.
Assembling information to assist in interpreting the
consequences of all base pair changes is the mission of
the Human Variome Project (HVP). InSiGHT has colla-
borated with the HVP, and now, due its coherence and
international organization, maintains a Locus Specific
Database which is seen as an exemplar for the unfolding
of the HVP across the whole genome.
Aim
To develop a single comprehensive LSDB relating to
MMR and other gene variants predisposing to hereditary
GI cancer, permitting the most expert interpretation of
the consequence of each variant through a systematic
interpretation process.
Methods
InSiGHT has appointed a range of committees to over-
see a range of activities related to its LSDBs for Heredi-
tary GI cancer. A strong collaboration has emerged
between the NCI funded Colon Cancer Family Register,
and InSIGHT, extending even further by invitation to all
parties interested in MMR repair – the INSILICO MMR
consortium. The work is bonded together through the
development of the Bayesian Likelihood Ratio for inter-
pretation of VUS, in a transatlantic and Australasian
effort.
Results
In the last two years, submissions have increased from
550 to over 13000. The InSIGHT MMR database
attracts over 20,000 hits per month from interested par-
ties. All the major MMR databases have been incorpo-
rated onto the InSiGHT MMR database (InSiGHT,
Newfoundland, functional assay databases) and there
have been large depositions of national data (German,
French, Canadian, Chinese). A phenotype dataset is
being finalized, assisted by the NCI. Functional studies
are being assimilated and further developed especially
from European expertise. The Bayesian Likelihood Ratio
approach to assigning pathogenicity informed by the
range of information available relevant to this, is being
lead by Sean Tavtigian, sponsored by IARC and now in
Utah. The interpretation committees are being sup-
ported by the Cancer Council of Victoria. Recently,
funding has been secured from the Melbourne based
H i c k sF o u n d a t i o nf o raf u l lt i m ec u r a t o ro ft h eM M R
database. The largest assembly of MMR families ever is
associated with the INSILICO consortium, underpinning
a range of research opportunities.
Conclusion
InSiGHT is proud of its achievements and leadership for
t h eH V P .M e m b e r so ft h eC G Aa r ee n c o u r a g e dt os u p -
port the InSiGHT databases, so the world can share
i n f o r m a t i o no nv a r i a n t sf o rthe general good and sup-
port of families with MMR mutations.
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